Andere Sprachen Hemostemix Inc.

Aktien

A2QQGU

CA4236943060

HEM

Verzögert Toronto S.E. Andere Börsenplätze 17:26:44 19.04.2024			% 5 Tage	% 1. Jan.
0,05 ^CAD	0,00 %		-9,09 %	-28,57 %

06.02.	Hemostemix gibt aktualisierte Ergebnisse der randomisierten klinischen Phase-II-Studie bekannt, die vom Journal of Biomedical Research and Environmental Sciences veröffentlicht wurden	CI
2023	Hemostemix Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.	07.03.
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	06.02.
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	06.02.
Hemostemix Clarifies its October 3, 2023 News Release	29.12.
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30.11.
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease	31.10.23
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease	30.10.23
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000	23.10.23
Hemostemix Closed Private Placement	03.10.23
Hemostemix Closed $320,125 Private Placement	03.10.23
Hemostemix Inc. announced that it has received CAD 0.320385 million in funding	03.10.23
Hemostemix Inc. announced that it expects to receive CAD 0.325125 million in funding	28.09.23
Hemostemix Announces Private Placement	27.09.23
Hemostemix Inc. announced that it has received CAD 0.72754 million in funding	27.09.23
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication	15.09.23
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications	30.08.23
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29.08.23
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement	15.08.23
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal	10.08.23
The Benefits of ACP-01 Stem Cell Therapy: Can it Save Limbs and thereby Lives	06.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hemostemix Inc.

Aktien

A2QQGU

CA4236943060

HEM

Andere Sprachen

Filter